FIGURE

Fig. 7

ID

ZDB-FIG-240607-105

Publication

Costa et al., 2024 - Zebrafish Avatar-test forecasts clinical response to chemotherapy in patients with colorectal cancer

Other Figures

All Figure Page

Back to All Figure Page

Fig. 7

Patients with a sensitive zAvatar-test have longer Progression-Free Survival.

a Kaplan–Meier survival curves were performed comparing the PFS of patients based on sensitivity or resistance of their zAvatar-test (taking into account the tree decision model). The PFS was calculated from the initiation of chemotherapy until either last observation or date of progression. b When analyzing patients from all stages, the zAvatar sensitive group had a longer mean PFS of 30.9 months compared to 7.5 months for the resistant group (N = 55 patients; p < 0.0001). c, d Similarly, in stage II/III patients the mean PFS was 37.0 months versus 11.3 months (N = 32 patients; p < 0.0001), and in stage IV patients the mean PFS was 11.4 months versus 5.9 months (N = 23 patients; p = 0.0063). Source data are provided as a Source Data file.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Nat. Commun.